Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ferrexpo cancels interim dividend

(Sharecast News) - Iron ore pellet producer Ferrexpo said on Tuesday that it was cancelling its interim dividend just days before it was due to be paid out, following a claim against its Ukrainian subsidiary. The company said it has decided not to go ahead with the 3.3 cents per share dividend following "unexpected" events in Ukraine relating to a claim against one of its subsidiaries, Ferrexpo Poltava Mining (FPM), which it disclosed at the end of last month.

Ferrexpo filed a cassation appeal to the Supreme Court in Ukraine on 30 January and an application to suspend enforcement of the decision of the Eastern Economic Court of Appeal in Kharkiv.

It said that until the Supreme Court has considered the application there is a risk of enforcement. However, Ferrexpo insisted the claims were "without merit" and said it had "compelling arguments" to vigorously defend its position.

"The board has reconsidered the interim dividend and decided to withdraw it. The board aims to resume its focus on shareholder returns at the appropriate time."

At 1310 GMT, the shares were down 5% at 76.85p.

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.